Rare disease player Ovid Therapeutics Inc. filed an S-1 with the SEC indicating its intention to raise up to $86.25 million in an IPO. Just three years old, the New York-based company previously raised $80 million in private capital – most of that in a $75 million series B – and snagged Jeremy Levin, former president and CEO of Teva Pharmaceutical Industries Ltd., to serve as its chairman. Levin, who helped to seed Ovid and holds 26.8 percent of its common stock, was named its CEO in 2015.